Let AI watch the worldβs key changes for you unkAI
unkAI continuously tracks the public intelligence and global changes you care about, and only alerts you when noteworthy new developments emerge. Subscribe for free by email β no repeated interruptions, no missed key changes.
Health
72 items Β· Recommended
Progress of new drug approvals by China NMPA in the second half of 2026
Follow up on the review progress and approval results of 8 blockbuster drugs rushing to market, and observe changes in indication coverage and market competition landscape.
Changes and dynamics of global respiratory virus activity
Combined with WHO weekly updates, track changes in the prevalence range, positive rate and variant strains of respiratory viruses such as influenza, COVID-19 and RSV around the world.
Progress in the research and development of multi-targeted innovative drugs in China
Track R&D breakthroughs, clinical trial progress, approval nodes and listing dynamics of drugs with multi-targeted systemic regulatory functions.
Progress of Phase III clinical trial of the innovative traditional Chinese medicine Qingshen Tongluo Granules
Follow up on the promotion rhythm of multi-center clinical trials, patient enrollment progress, and clinical trial data results, and pay attention to the final data unblinding and subsequent marketing application nodes.
Effective date of South Korea's new bee feed import quarantine regulations
Follow up on South Korea's new bee feed import quarantine regulations that will take effect on November 27, 2026, and pay attention to implementation requirements and changes in trade impacts.
FDA approval progress and developments of global innovative drugs
Track the key PDUFA milestones for new drugs in the second half of the year at FDA, follow the approval status of new drugs for different indications, and the changes in review progress adjustments.
Dynamics of subsequent clinical application of China's globally first-launched innovative drugs
Follow up on changes in clinical application scope, production capacity supply, and indication expansion after the launch of the world's first selective orexin type 2 receptor agonist.
Phase II Clinical Trial Milestone of Boehringer Pharmaceutical's BGM1812
Follow up on the changes of Phase II clinical trial launch timing, patient enrollment progress and trial result announcement milestones regarding Borui Pharmaceutical's innovative weight loss drug BGM1812.
Commercialization progress of invasive brain-computer interfaces
Follow up on clinical research, regulatory approval, indication expansion of invasive brain-computer interfaces, as well as corporate commercial landing and changes in market competition pattern.
Approval results of Hansoh Pharmaceutical's Olepeptide for listing in China
Follow up on the marketing review progress, result announcement time and subsequent changes in commercialization arrangements for Hansoh Pharmaceutical's GLP-1 target Olepeptide.
Approval result of Hengrui Medicine's Retatrutide for marketing in China
Follow the marketing approval progress, approved indications, approval time and commercial preparation updates of Hengrui Medicine's GLP-1R/GIPR dual-target Retatrutide.
FDA approval timeline for Eli Lilly's Orforglipron diabetes indication
Follow the FDA approval progress and result announcement schedule changes for Eli Lilly's oral small molecule GLP-1 Orforglipron in type 2 diabetes indication.